{"pmid":32281754,"title":"[Managing patients in dialysis and with kidney transplant infected with Covid-19].","text":["[Managing patients in dialysis and with kidney transplant infected with Covid-19].","We are in the midst of a health emergency that is totally new for us all and that requires a concerted effort, especially when it comes to safeguarding patients on hemodialysis, and kidney transplant recipients. Brescia is currently a very active cluster of infections (2918 cases on the 17/03/2020), second only to Bergamo. The way our structure is organised has allowed us to treat nephropathic patients directly within the Nephrology Unit, following of course a great deal of reshuffling; at the moment, we are treating 21 transplanted patients and 17 on hemodialysis. This has led us to adopt a systematic approach to handling this emergency, not only in managing inpatients, but also in researching the new disease. Our approach is mirrored in the guidelines attached to this article, originally intended for internal use only but potentially very useful to our colleagues, as they face the same exact problems. We have also started collecting data on our positive patients with the aim of understanding better the functioning of this disease and how best to manage it. If anyone is interested, we ask you to please get in touch with us, so we can coordinate our efforts.","G Ital Nefrol","Alberici, Federico","Del Barba, Elisa","Manenti, Chiara","Econimo, Laura","Valerio, Francesca","Pola, Alessandra","Maffei, Camilla","Possenti, Stefano","Gaggia, Paola","Movilli, Ezio","Bove, Sergio","Malberti, Fabio","Farina, Marco","Bracchi, Martina","Costantino, Ester Maria","Bossini, Nicola","Gaggiotti, Mario","Scolari, Francesco","32281754"],"abstract":["We are in the midst of a health emergency that is totally new for us all and that requires a concerted effort, especially when it comes to safeguarding patients on hemodialysis, and kidney transplant recipients. Brescia is currently a very active cluster of infections (2918 cases on the 17/03/2020), second only to Bergamo. The way our structure is organised has allowed us to treat nephropathic patients directly within the Nephrology Unit, following of course a great deal of reshuffling; at the moment, we are treating 21 transplanted patients and 17 on hemodialysis. This has led us to adopt a systematic approach to handling this emergency, not only in managing inpatients, but also in researching the new disease. Our approach is mirrored in the guidelines attached to this article, originally intended for internal use only but potentially very useful to our colleagues, as they face the same exact problems. We have also started collecting data on our positive patients with the aim of understanding better the functioning of this disease and how best to manage it. If anyone is interested, we ask you to please get in touch with us, so we can coordinate our efforts."],"journal":"G Ital Nefrol","authors":["Alberici, Federico","Del Barba, Elisa","Manenti, Chiara","Econimo, Laura","Valerio, Francesca","Pola, Alessandra","Maffei, Camilla","Possenti, Stefano","Gaggia, Paola","Movilli, Ezio","Bove, Sergio","Malberti, Fabio","Farina, Marco","Bracchi, Martina","Costantino, Ester Maria","Bossini, Nicola","Gaggiotti, Mario","Scolari, Francesco"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32281754","week":"202016|Apr 13 - Apr 19","keywords":["Brescia","Covid-19","dialysis","guidelines","nephrology","transplants"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Bergamo"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"_version_":1663989232744529920,"score":7.979339,"similar":[{"pmid":32281756,"title":"Covid-19 and its impact on nephropathic patients: the experience at Ospedale \"Guglielmo da Saliceto\" in Piacenza.","text":["Covid-19 and its impact on nephropathic patients: the experience at Ospedale \"Guglielmo da Saliceto\" in Piacenza.","Roberto Scarpioni and colleagues recount their experience with the Covid-19 epidemic at the Nephrology and Dialysis Center of the \"Guglielmo da Saliceto\" Hospital in Piacenza, where everybody is still fighting to this moment to contain the spread of the disease and face an increasingly unsustainable clinical situation. Piacenza is only 15 km away from the main cluster of cases in the country (Codogno, in the Lodi province) and, after the closure of the Hospital in Codogno, saw an escalation in the number of patients testing positive to Covid-19. The authors describe their efforts and the practices they adopted to contain the spread of the disease among inpatients visiting the hospital's Hemodialysis Clinic. They also reflect on some of the data available on the 25/03/2020, such as the number of patients testing positive and the mortality rate, unfortunately very high. Their aim is to help all colleagues that have yet to face this epidemic in its full force.","G Ital Nefrol","Scarpioni, Roberto","Manini, Alessandra","Valsania, Teresa","De Amicis, Sara","Albertazzi, Vittorio","Melfa, Luigi","Ricardi, Marco","Rocca, Chiara","32281756"],"abstract":["Roberto Scarpioni and colleagues recount their experience with the Covid-19 epidemic at the Nephrology and Dialysis Center of the \"Guglielmo da Saliceto\" Hospital in Piacenza, where everybody is still fighting to this moment to contain the spread of the disease and face an increasingly unsustainable clinical situation. Piacenza is only 15 km away from the main cluster of cases in the country (Codogno, in the Lodi province) and, after the closure of the Hospital in Codogno, saw an escalation in the number of patients testing positive to Covid-19. The authors describe their efforts and the practices they adopted to contain the spread of the disease among inpatients visiting the hospital's Hemodialysis Clinic. They also reflect on some of the data available on the 25/03/2020, such as the number of patients testing positive and the mortality rate, unfortunately very high. Their aim is to help all colleagues that have yet to face this epidemic in its full force."],"journal":"G Ital Nefrol","authors":["Scarpioni, Roberto","Manini, Alessandra","Valsania, Teresa","De Amicis, Sara","Albertazzi, Vittorio","Melfa, Luigi","Ricardi, Marco","Rocca, Chiara"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32281756","week":"202016|Apr 13 - Apr 19","keywords":["Covid-19","Emilia Romagna","Piacenza","dialysis","kidneys","nephropatic patients"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Piacenza","Codogno"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"_version_":1663989232657498112,"score":397.50146},{"pmid":32281755,"title":"An account of the first hours of the Covid-19 epidemic at the Nephrology Unit in Lodi (Lombardy).","text":["An account of the first hours of the Covid-19 epidemic at the Nephrology Unit in Lodi (Lombardy).","Marco Farina and colleagues give us their account of the first days of the Covid-19 epidemic in the Nephrology Unit of the Ospedale Maggiore in Lodi. From the news trickling through from Codogno on the 20th of February to the hospitalization, the following day, of the first dialytic patient with signs of pneumonia, who later tested positive to the virus. They tell us of how the hospital has been completely restructured in the wake of the epidemic, at remarkable speed and providing an example for others to follow, and the great sense self-sacrifice displayed by all medical personnel. After an overview of the clinical conditions of the 7 patients positive to the virus hospitalised in the following few days, they describe in some detail how symptomatic Covid+ patients are currently managed at the Ospedale Maggiore in Lodi.","G Ital Nefrol","Farina, Marco","Barbisoni, Francesco","Bertacchini, Silvia","Borettaz, Ilaria","Bucci, Raffaella","Maggio, Milena","Ronga, Chiara","32281755"],"abstract":["Marco Farina and colleagues give us their account of the first days of the Covid-19 epidemic in the Nephrology Unit of the Ospedale Maggiore in Lodi. From the news trickling through from Codogno on the 20th of February to the hospitalization, the following day, of the first dialytic patient with signs of pneumonia, who later tested positive to the virus. They tell us of how the hospital has been completely restructured in the wake of the epidemic, at remarkable speed and providing an example for others to follow, and the great sense self-sacrifice displayed by all medical personnel. After an overview of the clinical conditions of the 7 patients positive to the virus hospitalised in the following few days, they describe in some detail how symptomatic Covid+ patients are currently managed at the Ospedale Maggiore in Lodi."],"journal":"G Ital Nefrol","authors":["Farina, Marco","Barbisoni, Francesco","Bertacchini, Silvia","Borettaz, Ilaria","Bucci, Raffaella","Maggio, Milena","Ronga, Chiara"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32281755","week":"202016|Apr 13 - Apr 19","keywords":["Covid-19","Ospedale Maggiore di Lodi","dialysis","nephrology"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1663989232648060929,"score":276.71497},{"pmid":32282982,"title":"Early Impact of COVID-19 on Transplant Center Practices and Policies in the United States.","text":["Early Impact of COVID-19 on Transplant Center Practices and Policies in the United States.","COVID-19 is a novel, rapidly-changing pandemic: consequently, evidence-based recommendations in solid organ transplantation (SOT) remain challenging and unclear. To understand the impact on transplant activity across the US, and center-level variation in testing, clinical practice, and policies, we conducted a national survey between March 24-31, 2020 and linked responses to the COVID-19 incidence map. Response rate was a very high 79.3%, reflecting a strong national priority to better understand COVID-19. Complete suspension of live donor kidney transplantation was reported by 71.8% and live donor liver by 67.7%. While complete suspension of deceased donor transplantation was less frequent, some restrictions to deceased donor kidney transplantation were reported by 84.0% and deceased donor liver by 73.3%; more stringent restrictions were associated with higher regional incidence of COVID-19. Shortage of COVID-19 tests was reported by 42.5%. Respondents reported a total of 148 COVID-19 recipients from <1y to >10y post-transplant: 69.6% were kidney recipients, and 25.0% were critically ill. Hydroxychloroquine (HCQ) was used by 78.1% of respondents; azithromycin by 46.9%; tocilizumab by 31.3%, and remdesivir by 25.0%. There is wide heterogeneity in center-level response across the US; ongoing national data collection, expert discussion, and clinical studies are critical to informing evidence-based practices.","Am J Transplant","Boyarsky, Brian J","Chiang, Teresa Po-Yu","Werbel, William A","Durand, Christine M","Avery, Robin K","Getsin, Samantha N","Jackson, Kyle R","Kernodle, Amber B","Van Pilsum Rasmussen, Sarah E","Massie, Allan B","Segev, Dorry L","Garonzik-Wang, Jacqueline M","32282982"],"abstract":["COVID-19 is a novel, rapidly-changing pandemic: consequently, evidence-based recommendations in solid organ transplantation (SOT) remain challenging and unclear. To understand the impact on transplant activity across the US, and center-level variation in testing, clinical practice, and policies, we conducted a national survey between March 24-31, 2020 and linked responses to the COVID-19 incidence map. Response rate was a very high 79.3%, reflecting a strong national priority to better understand COVID-19. Complete suspension of live donor kidney transplantation was reported by 71.8% and live donor liver by 67.7%. While complete suspension of deceased donor transplantation was less frequent, some restrictions to deceased donor kidney transplantation were reported by 84.0% and deceased donor liver by 73.3%; more stringent restrictions were associated with higher regional incidence of COVID-19. Shortage of COVID-19 tests was reported by 42.5%. Respondents reported a total of 148 COVID-19 recipients from <1y to >10y post-transplant: 69.6% were kidney recipients, and 25.0% were critically ill. Hydroxychloroquine (HCQ) was used by 78.1% of respondents; azithromycin by 46.9%; tocilizumab by 31.3%, and remdesivir by 25.0%. There is wide heterogeneity in center-level response across the US; ongoing national data collection, expert discussion, and clinical studies are critical to informing evidence-based practices."],"journal":"Am J Transplant","authors":["Boyarsky, Brian J","Chiang, Teresa Po-Yu","Werbel, William A","Durand, Christine M","Avery, Robin K","Getsin, Samantha N","Jackson, Kyle R","Kernodle, Amber B","Van Pilsum Rasmussen, Sarah E","Massie, Allan B","Segev, Dorry L","Garonzik-Wang, Jacqueline M"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282982","week":"202016|Apr 13 - Apr 19","doi":"10.1111/ajt.15915","keywords":["clinical decision-making","epidemiology","guidelines","infectious agents - viral"],"source":"PubMed","topics":["Prevention","Treatment"],"weight":1,"locations":["US","US","United States"],"countries":["United States"],"countries_codes":["USA|United States"],"_version_":1663989232721461248,"score":236.08838},{"pmid":32282986,"title":"Clinical characteristics and immunosuppressants management of coronavirus disease 2019 in solid organ transplant recipients.","text":["Clinical characteristics and immunosuppressants management of coronavirus disease 2019 in solid organ transplant recipients.","Over 1,000,000 cases of coronavirus disease 2019 (COVID-19) have been confirmed since the worldwide outbreak began. Not enough data on infected solid organ transplant (SOT) recipients are available, especially data about the management of immunosuppressants. We report two cases of COVID-19 in two transplant recipients, with different treatments and prognoses. The first patient received liver transplantation due to hepatitis B virus-related hepatocellular carcinoma and was confirmed to have COVID-19 nine days later. Following a treatment regimen consisting of discontinued immunosuppressant use and low-dose methylprednisolone-based therapy, the patient developed acute rejection but eventually recovered. The other patient had undergone a renal transplant from a living related donor 17 years ago, and was admitted to the hospital because of persistent fever. This patient was also diagnosed with COVID-19. His treatment regimen consisted of reduced immunosuppressant use. No signs of rejection were observed during the regimen. In the end, the patient successfully recovered from COVID-19. These effectively treated cases can provide a basis for immunosuppressant management of COVID-19-positive SOT recipients.","Am J Transplant","Zhong, Zibiao","Zhang, Qiuyan","Xia, Haoyang","Wang, Aiping","Liang, Wenjin","Zhou, Wei","Zhou, Lihua","Liu, Xiao","Rao, Lingzhang","Li, Zhifeng","Peng, Zhiyong","Mo, Pingzheng","Xiong, Yong","Shaojun, Ye","Wang, Yanfeng","Ye, Qifa","32282986"],"abstract":["Over 1,000,000 cases of coronavirus disease 2019 (COVID-19) have been confirmed since the worldwide outbreak began. Not enough data on infected solid organ transplant (SOT) recipients are available, especially data about the management of immunosuppressants. We report two cases of COVID-19 in two transplant recipients, with different treatments and prognoses. The first patient received liver transplantation due to hepatitis B virus-related hepatocellular carcinoma and was confirmed to have COVID-19 nine days later. Following a treatment regimen consisting of discontinued immunosuppressant use and low-dose methylprednisolone-based therapy, the patient developed acute rejection but eventually recovered. The other patient had undergone a renal transplant from a living related donor 17 years ago, and was admitted to the hospital because of persistent fever. This patient was also diagnosed with COVID-19. His treatment regimen consisted of reduced immunosuppressant use. No signs of rejection were observed during the regimen. In the end, the patient successfully recovered from COVID-19. These effectively treated cases can provide a basis for immunosuppressant management of COVID-19-positive SOT recipients."],"journal":"Am J Transplant","authors":["Zhong, Zibiao","Zhang, Qiuyan","Xia, Haoyang","Wang, Aiping","Liang, Wenjin","Zhou, Wei","Zhou, Lihua","Liu, Xiao","Rao, Lingzhang","Li, Zhifeng","Peng, Zhiyong","Mo, Pingzheng","Xiong, Yong","Shaojun, Ye","Wang, Yanfeng","Ye, Qifa"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282986","week":"202016|Apr 13 - Apr 19","doi":"10.1111/ajt.15928","keywords":["COVID-19","Clinical characteristics","Immunosuppressant","Solid organ transplant recipient"],"source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1663989232614506496,"score":234.90422},{"pmid":32279418,"title":"Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19).","text":["Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19).","During the novel coronavirus pandemic, organ transplant recipients represent a frail susceptible category due to long-term immunosuppressive therapy. For this reason, clinical manifestations may differ from general population and different treatment approaches may be needed. We present the case of a 36-year-old kidney transplanted woman affected by Senior-Loken syndrome diagnosed with COVID-19 pneumonia after a contact with her positive mother. Initial symptoms were fatigue, dry cough and coryza; she never had fever nor oxygen supplementation. Hydroxychloroquine and lopinavir/ritonavir were started, and the antiviral drug was replaced with darunavir/cobicistat after two days for diarrhea. Immunosuppressant levels were closely monitored, and we observed very high tacrolimus trough levels despite initial dose reduction. The patient was left with steroid therapy alone. The peculiarity of clinical presentation and the management difficulties represent the flagship of our case-report. We stress the need for guidelines in transplant recipients with COVID-19 infection with particular regard to the management of therapy.","Transpl Infect Dis","Bartiromo, Marilu","Borchi, Beatrice","Botta, Annarita","Bagala, Alfredo","Lugli, Gianmarco","Tilli, Marta","Cavallo, Annalisa","Xhaferi, Brunilda","Cutruzzula, Roberta","Vaglio, Augusto","Bresci, Silvia","Larti, Aida","Bartoloni, Alessandro","Cirami, Calogero","32279418"],"abstract":["During the novel coronavirus pandemic, organ transplant recipients represent a frail susceptible category due to long-term immunosuppressive therapy. For this reason, clinical manifestations may differ from general population and different treatment approaches may be needed. We present the case of a 36-year-old kidney transplanted woman affected by Senior-Loken syndrome diagnosed with COVID-19 pneumonia after a contact with her positive mother. Initial symptoms were fatigue, dry cough and coryza; she never had fever nor oxygen supplementation. Hydroxychloroquine and lopinavir/ritonavir were started, and the antiviral drug was replaced with darunavir/cobicistat after two days for diarrhea. Immunosuppressant levels were closely monitored, and we observed very high tacrolimus trough levels despite initial dose reduction. The patient was left with steroid therapy alone. The peculiarity of clinical presentation and the management difficulties represent the flagship of our case-report. We stress the need for guidelines in transplant recipients with COVID-19 infection with particular regard to the management of therapy."],"journal":"Transpl Infect Dis","authors":["Bartiromo, Marilu","Borchi, Beatrice","Botta, Annarita","Bagala, Alfredo","Lugli, Gianmarco","Tilli, Marta","Cavallo, Annalisa","Xhaferi, Brunilda","Cutruzzula, Roberta","Vaglio, Augusto","Bresci, Silvia","Larti, Aida","Bartoloni, Alessandro","Cirami, Calogero"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32279418","week":"202016|Apr 13 - Apr 19","doi":"10.1111/tid.13286","keywords":["COVID-19","drug-drug interaction","kidney transplant"],"source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1663890921989603328,"score":213.32098}]}